Scholarlink

Background <p>Inflammatory bowel disease, encompassing ulcerative colitis (UC) and Crohn’s disease, is increasing in prevalence in Western populations. Infliximab (IFX) is a standard treatment for severe UC. Evidence suggests combination therapy with IFX and azathioprine (AZA) improves clinical outcomes. However, AZA increases non-Hodgkin lymphoma (NHL) risk.</p> Aims <p>We modeled the cost-effectiveness of combination therapy with IFX and AZA versus IFX monotherapy.</p> Methods <p>We used a Markov model to simulate 25-year-old patients with UC over a 5-year time horizon in eight-week cycles. Patients received monotherapy, combination therapy for all 5&#xa0;years (“continuous combination therapy”), or combination therapy for 1&#xa0;year followed by monotherapy (“one-year combination therapy”). We measured quality-adjusted life years (QALYs) and costs of drug therapy, complications, and NHL.</p> Results <p>With monotherapy, patients experienced 3.263 QALYs and 6.84 flares; with 1-year combination therapy, 3.349 QALYs and 5.73 flares; and with continuous combination therapy, 3.351 QALYs and 5.67 flares. After 5&#xa0;years, NHL incidence was 0.188% with monotherapy; 0.207% with 1-year combination therapy; and 1.121% with continuous combination therapy. Healthcare costs were $312,500 for monotherapy, $264,700 for 1-year combination therapy, and $265,400 for continuous combination therapy. Results were robust across sensitivity analyses.</p> Conclusions <p>Combination therapy with IFX and AZA is a cost-saving strategy for moderate-to-severe UC, providing superior outcomes and lower costs compared to IFX monotherapy. Both 1-year and continuous combination therapy achieve comparable health outcomes. Short-term combination therapy may be preferable, as it captures the benefits of improved UC management while avoiding the deleterious effects of long-term exposure to thiopurines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Infliximab Monotherapy Versus Infliximab and Azathioprine Combination Therapy in Patients with Ulcerative Colitis: A Cost-Effectiveness Analysis

  • 期刊论文

  • 发表日期：

    2026年2月22日

查看全文
  • Paul Dupenloup,
  • Ola Selnes,
  • Sarah E. Streett,
  • Margaret L. Brandeau,
  • Grant E. Barber

摘要

Background

Inflammatory bowel disease, encompassing ulcerative colitis (UC) and Crohn’s disease, is increasing in prevalence in Western populations. Infliximab (IFX) is a standard treatment for severe UC. Evidence suggests combination therapy with IFX and azathioprine (AZA) improves clinical outcomes. However, AZA increases non-Hodgkin lymphoma (NHL) risk.

Aims

We modeled the cost-effectiveness of combination therapy with IFX and AZA versus IFX monotherapy.

Methods

We used a Markov model to simulate 25-year-old patients with UC over a 5-year time horizon in eight-week cycles. Patients received monotherapy, combination therapy for all 5 years (“continuous combination therapy”), or combination therapy for 1 year followed by monotherapy (“one-year combination therapy”). We measured quality-adjusted life years (QALYs) and costs of drug therapy, complications, and NHL.

Results

With monotherapy, patients experienced 3.263 QALYs and 6.84 flares; with 1-year combination therapy, 3.349 QALYs and 5.73 flares; and with continuous combination therapy, 3.351 QALYs and 5.67 flares. After 5 years, NHL incidence was 0.188% with monotherapy; 0.207% with 1-year combination therapy; and 1.121% with continuous combination therapy. Healthcare costs were $312,500 for monotherapy, $264,700 for 1-year combination therapy, and $265,400 for continuous combination therapy. Results were robust across sensitivity analyses.

Conclusions

Combination therapy with IFX and AZA is a cost-saving strategy for moderate-to-severe UC, providing superior outcomes and lower costs compared to IFX monotherapy. Both 1-year and continuous combination therapy achieve comparable health outcomes. Short-term combination therapy may be preferable, as it captures the benefits of improved UC management while avoiding the deleterious effects of long-term exposure to thiopurines.